PTSM: Pharmaceutical Technology Sourcing and Management, Jun 9, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jun 9, 2010
Manufacturing
FDA Considers Ways to Improve Transparency in the Supply Chain
By Patricia Van Arnum
FDA issues draft proposals on ways to improve its disclosure on information relating to import procedures, inspections, and Warning Letters.
Outsourcing
Waste Not, Want Not
By Eric Langer
Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.
CSR and Sustainability Forum
The Pharmaceutical Industry Comes to the Aid of Haiti
By Patricia Van Arnum
The pharmaceutical industry provided immediate aid for the relief efforts in Haiti and is proceeding with plans to assist with long-term recovery.
AAAS Marries Science and Human Rights
By Patricia Van Arnum
The American Association for the Advancement of Science rolls out several initiatives to increase partnerships and communication on human rights between scientific groups and between scientific and human rights groups.
CSR and Sustainability Roundup
A roundup of developments on corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here